Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy

Abstract

The consumption of low-dose aspirin (LDA) to prevent cardiovascular disease continues to increase worldwide. Consequently, the number of chronic LDA users seeking dental procedures that require complementary acute anti-inflammatory medication has also grown. Considering the lack of literature evaluating this interaction, we analyzed the gastric and renal effects caused by a selective COX-2 inhibitor (etoricoxib) and a non-selective COX-2 inhibitor (ibuprofen) nonsteroidal anti-inflammatory drug (NSAID) in rats receiving chronic LDA therapy. Male Wistar rats were divided into six experimental groups (carboxymethylcellulose (CMC) - vehicle; LDA; LDA + ibuprofen; ibuprofen; LDA + etoricoxib; and etoricoxib) and submitted to long-term LDA therapy with a subsequent NSAID administration for three days by gavage. After the experimental period, we analyzed gastric and renal tissues and quantified serum creatinine levels. The concomitant use of LDA with either NSAID induced the highest levels of gastric damage when compared to the CMC group (F = 20.26, p < 0.05). Treatment with either LDA or etoricoxib alone was not associated with gastric damage. No significant damage was observed on kidney morphology and function (F = 0.5418, p > 0.05). These results suggest that even the acute use of an NSAID (regardless of COX-2 selectivity) can induce gastric damage when combined with the long-term use of low-dose aspirin in an animal model. Additional studies, including clinical assessments, are thus needed to clarify this interaction, and clinicians should be careful of prescribing NSAIDs to patients using LDA.

Effects of early antiplatelet therapy after splenectomy with gastro‐oesophageal devascularization

“…Aspirin exerts its antiplatelet effect by inhibiting cyclooxygenase and reducing the synthesis of TXA2. 17 Dipyridamole and aspirin have a synergistic effect in inhibiting the formation of TXA2, but dipyridamole has a stronger antiplatelet aggregation effect, mainly through inhibition of phosphodiesterase activity, increase in adenosine cyclase activity and increase in the level of platelet endocyclic phosphate. In this study, we selected dipyridamole and aspirin as the regular PVT prevention regimen.…”

Masking the Taste of Fixed-Dose Combination Drugs: Particular NSAIDs Can Efficiently Mask the Bitterness of Famotidine

“…However, since prostaglandins protect against gastric acid, gastric mucosal damage has been reported as a side effect of long-term administration of NSAIDs. 1,2) Therefore, fixed-dose combinations (FDC) of NSAIDs with acid secretion inhibitors have been developed with the advantage of reduced side effects, reduced number of medications taken, and improved adherence. 3,4) Famotidine (FAM) is a histamine receptor antagonist that decreases gastric acid secretion, used widely for treating gastric ulcers.…”

Estudio comparativo de la acción gastroprotectora del Plantago major y el omeprazol sobre la gastritis inducida por la administración de ketorolaco

“…Estos fármacos, de acuerdo al tiempo en el cual son consumidos, presentan diferentes afectos adversos, como la hepatotoxicidad o nefrotoxicidad, pero la gastrolesividad es el efecto adverso predominante de estos fármacos; la cual puede presentarse como gastritis y posteriormente como úlceras gástricas (2) . Se sugiere que la gastrolesividad de los AINE está relacionada a la inespecificidad de estos para unirse a la enzima ciclooxigenasa-2, lo cual es perjudicial para el paciente tratado con un esquema terapéutico basado en varios días de administración del fármaco; aun así, en muchos casos es necesaria la administración de este por un tiempo prolongado (3,4) . En odontología los esquemas terapéuticos posoperatorios muchas veces están por dentro de los 3 a 5 días, con la administración de estos fármacos 2 o 3 veces al día, lo cual puede desencadenar en el paciente algún tipo de lesión gástrica, ya sea de manera superficial o profunda (5,6) .…”